PressurePace™ BRT
Heart Failure with Preserved Ejection Fraction (HFpEF) caused by hypertension
Pivotal Trial PreparationActive
Key Facts
Indication
Heart Failure with Preserved Ejection Fraction (HFpEF) caused by hypertension
Phase
Pivotal Trial Preparation
Status
Active
Company
About BaroPace
BaroPace is pioneering blood pressure-regulated therapy (BRT) for cardiac pacemakers, targeting a fundamental shift in pacemaker control. Its PressurePace™ algorithm is designed to dynamically adjust heart rate based on real-time blood pressure, aiming to improve outcomes for patients with HFpEF and hypertension, conditions with massive unmet needs. The company is preparing for a pivotal trial (RelieveHFpEF-III) in 2026 and posits that its technology could enhance quality of life for all pacemaker patients while significantly reducing healthcare costs. If successful, BaroPace's platform could expand the pacemaker market and establish a new standard of care.
View full company profile